Pomalidomide and Carfilzomib in Multiple Myeloma

Insight From: Noopur Raje, MD, Dana-Farber; Sagar Lonial, MD, Winship, and
Ann McNeill, RN, APN, JTCC
 
Published Online: Thursday, August 28, 2014
For High-Definition, Click
Although new agents, such as the immunomodulatory agent pomalidomide and the proteasome inhibitor carfilzomib, are widely used in the treatment of patients with relapse refractory multiple myeloma, there is no one treatment regimen that clinicians prefer over another. A patient’s comorbidities are important to consider when selecting one of these drugs because they have different side effect profiles, according to Noopur Raje, MD. He explains that due to the cardiac toxicities associated with carfilzomib, he prefers to treat patients who have cardiovascular-related conditions with pomalidomide. Patients who present with a more aggressive relapse or already existing myelosuppression may benefit from treatment with carfilzomib, which is associated with less myelosuppression. Raje adds that many patients are given both drugs in combination.

Ann McNeill, RN, APN discusses the management of drug toxicities with pomalidomide. She explains that toxicities are managed fairly aggressively, and are therefore unlikely to be the cause of therapy discontinuation. She notes that in most situations, therapy is continued until disease progression occurs.

Sagar Lonial, MD adds that the drug’s dosing and administration are factors to consider. Carfilzomib is given twice-weekly via infusion. Pomalidomide is a once-daily oral medication, which can offer added convenience for patients. Deciding between these 2 drugs can depend on a patient’s history with other similar agents, says Lonial. If a patient has had a good response with a prior immunomodulatory agent, he or she may respond well to pomalidomide. Similarly, a patient who has exhibited sensitivity to a proteasome inhibitor is likely to benefit from carfilzomib.

Lonial notes that patients in the relapse setting who have renal dysfunction can be challenging to treat. Generally, modest dose reduction is warranted in these patients. In older patients who have relapsed, it is common to use either lenalidomide and dexamethasone, or bortezomib and dexamethasone, he says. For patients with end-stage disease, combination therapy with 2 or 3 agents is common.
View More From This Discussion
Episode 1 Imaging and Treatment Advances in Multiple Myeloma
Episode 2 High-Risk and Smoldering Multiple Myeloma
Episode 3 Treatment Options in Newly Diagnosed Multiple Myeloma
Episode 4 Treatment Decisions in Relapsed/Refractory Myeloma
Episode 5 Pomalidomide in Refractory Multiple Myeloma
Episode 6 Pomalidomide and Carfilzomib in Multiple Myeloma
Episode 7 Maintenance Therapy for Patients With Multiple Myeloma
Episode 8 Management of Adverse Events in Multiple Myeloma
Episode 9 Emerging Agents for Multiple Myeloma

 
Online CME Activities
Free CME from PER
Highlights From the 13th Annual International Congress on the Future of Breast Cancer®
Pancreatic Cancer: Novel and Emerging Approaches to Early Detection and Treatment
Oncology Best Practice: Challenges in Treating Chronic Lymphocytic Leukemia – The Older Patient and Comorbid Conditions
OncoLogue: Breast Cancer Cases
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.
 
More Reading
Publications
$auto_registration$